Skip to main content
SpringerLink
Log in

Male Sexual Dysfunction in Diabetes Mellitus

  • Reference work entry
  • First Online:
Book cover Principles of Diabetes Mellitus

Abstract

Erectile dysfunction (ED), also known as impotence, is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual function. Based on these data and the US population projection for the year 2020 of more than 74 million men 45–84 years old, ED will affect more than 38 million men and millions more over the age of 84. Diabetic men have a more than threefold increase in risk of ED compared to their nondiabetic counterparts. Diabetes mellitus (DM) is a common chronic disease affecting 285 million people and is expected to increase to 7.7% by 2030. Because both ED and DM are so prevalent, it is not surprising the two are associated. ED is reported to occur in more than 50% of men with diabetes. The penis is a complex vascular organ that requires the coordination of an initiated spinal reflex to a vascular process in which nerves, sinusoidal and vascular endothelium, and smooth muscle (SM) cells are involved to achieve satisfactory penile erection. In men with DM who have impaired erection, there is the inability to either obtain or maintain a state of penile rigidity sufficient for satisfactory intercourse. In those having DM with ED, there is a panoply of possible adverse effects on the neurological function, vascular (including smooth muscle and endothelium) supply, cell membranes, contractile proteins, and a myriad of neurotransmitters and second messengers that can interfere with the normal mechanism of erection. These potential mechanisms and modern therapies for ED are reviewed as a starting point for understanding the basis of this important physiological function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. NIH Consensus Developmen. Panel on impotence. NIH Consensus Conference. J Am Med Assoc. 1993;270:83–90.

    Article  Google Scholar 

  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.

    Article  CAS  PubMed  Google Scholar 

  3. http://www.census.gov/population/projections/data/national/2014/summarytables.html

  4. Ayta IA, Mckinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50–6.

    Article  CAS  PubMed  Google Scholar 

  5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

    Article  CAS  PubMed  Google Scholar 

  6. Kaiser FE, Korenman SG. Impotence in diabetic men. Am J Med. 1988;85(5A):147–52.

    Article  CAS  PubMed  Google Scholar 

  7. Mazzilli R, Elia J, Delfino M, Benedetti F, Scordovillo G, Mazzilli F. Prevalence of diabetes mellitus (DM) in a population of men affected by erectile dysfunction (ED). Clin Ter. 2015;166(5):e317–20.

    CAS  PubMed  Google Scholar 

  8. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18(4):279–83.

    Article  CAS  PubMed  Google Scholar 

  9. McCulloch DK, Young RJ, Prescott RJ, Campbell IW, Clarke BF. The natural history of impotence in diabetic men. Diabetologia. 1984;26:437–40.

    Article  CAS  PubMed  Google Scholar 

  10. Fedele D, Bartolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colle E, Lavezzari M, Landoni M, Parazzini F. Erectile dysfunctoon in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol. 2000;29(3):524–31.

    Article  CAS  PubMed  Google Scholar 

  11. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin N Am. 1995;22:699–709.

    CAS  Google Scholar 

  12. Ellenberg M. Impotence in diabetes: the neurologic factor. Ann Intern Med. 1971;75:213–9.

    Article  CAS  PubMed  Google Scholar 

  13. Ellenberg M. Sexual function in diabetic patients. Ann Intern Med. 1980;92:331–3.

    Article  CAS  PubMed  Google Scholar 

  14. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. Urology. 1999;161:5–11.

    Article  CAS  Google Scholar 

  15. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients. J Urol. 1985;133:34–8.

    Article  CAS  PubMed  Google Scholar 

  16. Cummings MH, Alexander WD. Erectile dysfunction in patients with diabetes. Hosp Med. 1999;60:638–44.

    Article  CAS  PubMed  Google Scholar 

  17. Pop-Busui R, Hotaling J, Braffett BH, Cleary PA, Dunn RL, Martin CL, Jacobson AM, Wessells H, Sarma AV, DCCT/EDIC Research Group. Cardiovascular autonomic neuropathy, erectile dysfunction and lower urinary tract symptoms in men with type 1 diabetes: findings from the DCCT/EDIC. J Urol. 2015;193(6):2045–51.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Musicki B, Bella AJ, Bivalacqua TJ, et al. Basic science evidence for the link between erectile dysfunction and cardiometabolic dysfunction. J Sex Med. 2015;12:2233–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lehman TP, Jacobs JA. Etiology of diabetic impotence. J Urol. 1983;129:291–4.

    Article  CAS  PubMed  Google Scholar 

  20. Christ GJ, Brink PR, Melman A, Spray DC. The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle. Int J Impot Res. 1993;5:77–96.

    CAS  PubMed  Google Scholar 

  21. Andersson K-E. Mechanisms of Penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev. 2011;63:811–59.

    Article  CAS  PubMed  Google Scholar 

  22. Goldstein I. Impotence (editorial). J Urol. 1994;51:1533–4.

    Article  Google Scholar 

  23. Lue TF. Erectile dysfunction associated with cavernous and neurological model (editorial). J Urol. 1994;151:890–1.

    Article  CAS  PubMed  Google Scholar 

  24. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191.

    CAS  PubMed  Google Scholar 

  25. Lerner SE, Melman A, Christ CJ. A review of erectile dysfunction: new insights and more questions. J Urol. 1993;149:1246–55.

    Article  CAS  PubMed  Google Scholar 

  26. Wagner G, Brindley GS. The effect of atropine, alpha and beta blockers on human penile erection: a controlled pilot study. In: Zorgniotti AW, Rossi G, editors. Vasculogenic impotence. Proceedings of the first international conference on gorpus cavernosum revascularization. Springfield: Charles C Thomas Publishers; 1980. p. 77–81.

    Google Scholar 

  27. Saenz de Tejada I, Goldstein I. Diabetic penile neuropathy. Urol Clin N Am. 1988;15:17–22.

    CAS  Google Scholar 

  28. Blanco R, Saenz de Tejada I, Goldstein I, Krane RJ, Wotiz HH, Cohen RA. Dysfunctional penile cholinergic nerves in diabetic impotent men. J Urol. 1990;144:278–80.

    Article  CAS  PubMed  Google Scholar 

  29. Melman A, Henry DP. The possible role of the catecholamines of the corpora in penile erection. Urology. 1979;121:419–21.

    Article  CAS  Google Scholar 

  30. Felten DL, Felten SY, Melman A. Noradrenergic innervation of the penis in control and streptozotocin-diabetic rats: evidence of autonomic neuropathy. Anat Rec. 1983;206:49–59.

    Article  CAS  PubMed  Google Scholar 

  31. Melman A, Henry DP, Felten DL. Catecholamine content of penile corpora in patients with diabetes associated impotence. Surg Forum. 1978;29:634–6.

    CAS  PubMed  Google Scholar 

  32. Melman A, Henry DP, Felten DL, O’Connor BL. Effect of diabetes upon penile sympathetic nerves in impotent patients. South Med J. 1980;73:307–9.

    Article  CAS  PubMed  Google Scholar 

  33. Melman A, Henry DP, Felten DL, O’Connor BL. Alteration of the penile corpora in patients with erectile impotence. Investig Urol. 1980;17:474–7.

    CAS  Google Scholar 

  34. Christ GJ, Maayani S, Valcic M, Melman A. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol. 1990;101:375–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Chang S, Hypolite J, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res. 2003;15:53–62.

    Article  CAS  PubMed  Google Scholar 

  36. Gu J, Polak JM, Probert L, Islam KN, et al. Peptidergic innervation of the human male genital tract. J Urol. 1983;130:386–91.

    Article  CAS  PubMed  Google Scholar 

  37. Adaiken PG, Kottegoda SR, Ratnam SS. Is vasoactive intestinal peptide the principal transmitter involved in human penile erection? J Urol. 1986;135:638–40.

    Article  Google Scholar 

  38. Gu J, Polak J, Lazarides M, Morgan R, et al. Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet. 1984;2:315–8.

    Article  CAS  PubMed  Google Scholar 

  39. Crowe R, Lincoln J, Blacklay FP, Pryor JP, Lumley JS, Burnstock G. Vasoactive intestinal polypeptide-like immunoreactive nerves in diabetic penis. A comparison between streptozocin-treated rats and man. Diabetes. 1983;32:1075–7.

    Article  CAS  PubMed  Google Scholar 

  40. Lincoln J, Crowe R, Blacklay PF, Pryor JP, Lumley JS, Burnstock G. Changes in the VIPergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic important males. J Urol. 1987;137:1053–9.

    Article  CAS  PubMed  Google Scholar 

  41. Azadzoi K, Kim N, Brown ML, Goldstein I, Cohen RA, Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. Urology. 1992;147:220–5.

    Article  CAS  Google Scholar 

  42. Saenz de Tejada I, Carson MP, de las Morenas A, Goldstein I, Triash AM. Endothelin: localization, synthesis, activity, and receptor types in human penile corpus cavernosum. Am J Physiol. 1991;261:H1078–85.

    CAS  PubMed  Google Scholar 

  43. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434–40.

    Article  CAS  PubMed  Google Scholar 

  44. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.

    Article  CAS  PubMed  Google Scholar 

  45. Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest. 1992;90:1023–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Granchi S, Vannelli GB, Vignozzi L, et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod. 2002;8:1053–64.

    Article  CAS  PubMed  Google Scholar 

  47. Christ GJ, Lerner SE, Kim DC, Melman A. Endothelin-1 as a putative modulator of erectile dysfunction: 1.Characteristics of contraction of isolated corporal tissue strips. J Urol. 1995;153:1998–2003.

    Article  CAS  PubMed  Google Scholar 

  48. Makino A, Kamata K. Time-course changes in plasma endothelin-1 and its effects on the mesenteric arterial bed in streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2000;2:47–55.

    Article  CAS  PubMed  Google Scholar 

  49. Jesmin S, Hattori Y, Maeda S, Zaedi S, Sakuma I, Miyauchi T. The subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by the normalization of the upregulated endothelin system in rats. Am J Physiol Heart Circ Physiol. 2006;290:H2146–54.

    Article  CAS  PubMed  Google Scholar 

  50. Shestakova MV, Jarek-Martynowa IR, Ivanishina NS, et al. Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2005;68(Suppl1):S65–72.

    Article  CAS  PubMed  Google Scholar 

  51. Migdalis IN, Kalogeropoulou K, Karmaniolas KD, Varvarigos N, Mortzos G, Cordopatis P. Plasma levels of endothelin and early carotid atherosclerosis in diabetic patients. Res Commun Mol Pathol Pharmacol. 2000;108:15–25.

    CAS  PubMed  Google Scholar 

  52. Francavilla S, Properzi G, Bellini C, Marino G, Ferri C, Santucci A. Endothelin-1 in diabetic and nondiabetic men with erectile dysfunction. J Urol. 1997;158:1770–4.

    Article  CAS  PubMed  Google Scholar 

  53. Nakamuta M, Takayanagi R, Sakai Y, et al. Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor. Biochem Biophys Res Commun. 1991;177:34–9.

    Article  CAS  PubMed  Google Scholar 

  54. Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, Masaki T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun. 1991;178:656–63.

    Article  CAS  PubMed  Google Scholar 

  55. Bell CR, Sullivan ME, Dashwood MR, Muddle JR, Morgan RJ. The density and distribution of endothelin 1 and endothelin receptor subtypes in normal and diabetic rat corpus cavernosum. Br J Urol. 1995;76:203–7.

    Article  CAS  PubMed  Google Scholar 

  56. Endo K, Matsumoto T, Kobayashi T, Kasuya Y, Kamata K. Diabetes-related changes in contractile responses of stomach fundus to endothelin-1 in streptozotocin-induced diabetic rats. J Smooth Muscle Res. 2005;41:35–47.

    Article  PubMed  Google Scholar 

  57. Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP, Morgan RJ. Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J Urol. 1997;158:1966–72.

    Article  CAS  PubMed  Google Scholar 

  58. Kim N, Azadzoi K, Goldstein I, Saenz de Tejada I. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest. 1991;88:112–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90–4.

    Article  CAS  PubMed  Google Scholar 

  60. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16(Supple 1):S4–7.

    Article  CAS  PubMed  Google Scholar 

  61. Seftel AD, Vaziri ND, Ni Z, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50:1016–26.

    Article  CAS  PubMed  Google Scholar 

  62. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration of diabetes mellitus – a nitric oxide-dependent phenomenon. Br J Pharmacol. 1999;128:1804–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factors genes and protein expression in an animal model. Int J Impot Res. 1999;11:123–32.

    Article  CAS  PubMed  Google Scholar 

  64. Sullivan M, Thompson CS, Mikhailidis DP, Morgan RJ, Angelini GD, Jeremy JY. Differential alterations of prostacyclin, cyclic AMP and cyclic GMP formation in the corpus cavernosum of the diabetic rabbit. Br J Urol. 1998;82:578–84.

    Article  CAS  PubMed  Google Scholar 

  65. Elabbady AA, Gagnon C, Hassouna MM, Begin LR, Elhilali MM. Diabetes mellitus increases nitric oxide synthase in penises but not in major pelvic ganglia of rats. Br J Urol. 1995;76:196–202.

    Article  CAS  PubMed  Google Scholar 

  66. Basar MM, Yildiz M, Soylemezoglu F, et al. Histopathological changes and nitric oxide synthase activity in corpus cavernosum from rats with neurogenic erectile dysfunction. BJU Int. 1999;83:101–7.

    Article  CAS  PubMed  Google Scholar 

  67. Miller MA, Morgan RJ, Thompson CS, Mikhailidis DP, Jeremy JY. Hydrolysis of cyclic guanosine monophosphate and cyclic adenosine monophosphate by the penis and aorta of the diabetic rat. Br J Urol. 1996;78:252–6.

    Article  CAS  PubMed  Google Scholar 

  68. Angulo J, Gonzalez-Corrochano R, Cuevas P, Fernandez A, La Fuente JM, Rolo F, Allona A, Saenz de Tejada I. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med. 2010;7(2 Pt 1):758–68.

    Article  CAS  PubMed  Google Scholar 

  69. Ferrini MG, Rivera S, Moon J, Venet D, Rafjer J, Gonzalez-Cadavid NF. The genetic inactivation of inducible nitiric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora in type 1 diabetes. J Sex Med. 2010;7:3033–44.

    Article  CAS  PubMed  Google Scholar 

  70. Wang T, Li M, Yuan H, Zhan Y, Xu H, Wang S, Yang W, Liu J, Ye Z, Li LC. saRNA guided iNOS up-regultion improves erectile function of diabetic rats. J Urol. 2013;190(2):790–8.

    Article  CAS  PubMed  Google Scholar 

  71. Mandosi E, Giannetta E, Filardi T, Lococo M, Bertolini C, Fallarino M, Gianfrilli D, Venneri MA, Lenti L, Lenzi A, Morano S. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opin Ther Targets. 2015;19:1617–22.

    Article  CAS  PubMed  Google Scholar 

  72. Ellati RT, Dokun AO, Kavoussi PK, Steers WD, Annex BH, Lysiak JJ. Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. J Sex Med. 2013;10(2):362–9.

    Article  CAS  PubMed  Google Scholar 

  73. Jin HR, Kim WJ, Song JS, Piao S, Tumurbaatar M, Shin SH, Choi MJ, Tuvshintur B, Song KM, Kwon MH, Yin GN, Koh GY, Ryu JK, Suh JK. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med. 2010;7(11):3635–46. doi:10.1111/j.1743-6109.2010.01925.x.

    Article  CAS  PubMed  Google Scholar 

  74. Jensen SB. Sexual dysfunction in insulin-treated diabetes: a six-year follow-up study of 101 patients. Arch Sex Behav. 1986;15:271–83.

    Google Scholar 

  75. Kolodny RC, Kahn CB, Goldstein HH, Barnett DM. Sexual dysfunction in diabetic men. Diabetes. 1974;23:306–9.

    Article  CAS  PubMed  Google Scholar 

  76. Deutsch S, Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. J Am Med Assoc. 1980;244:2430–2.

    Article  CAS  Google Scholar 

  77. Christ GJ, Hsieh Y, Zhao W, et al. Effects of streptozotocin-induced diabetes on bladder and erectile (dys)function in the same rat in vivo. BJU Int. 2006;97:1076–82.

    Article  PubMed  Google Scholar 

  78. Faerman I, Glocer L, Fox D, Jadzinsky MN, Rapaport M. Impotence and diabetes. Histological studies of the autonomic nervous fibers of the corpora cavernosa in impotent diabetic males. Diabetes. 1974;23:971–6.

    Article  CAS  PubMed  Google Scholar 

  79. Bermelmans BL, Meuleman EJ, Doesburg WH, Notermans SL, Debruyne FM. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol. 1994;151:884–9.

    Article  Google Scholar 

  80. Schaumberg H, Zotova E, Raine C, et al. Experimental autonomic neuropathy. Ann Neurol. 2007;62:S65.

    Google Scholar 

  81. Zotova EG, Schaumburg HH, Raine CS, Cannella B, Tar M, Melman A, Arezzo JC. Effects of hyperglycemia on rat cavernous nerve axons: a functional and ultrastructural study. Exp Neurol. 2008;213(2):439–47. doi:10.1016/j.expneurol.2008.07.009, Epub 2008 Jul 18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Melman A, Zotova E, Kim M, Arezzo J, Davies K, DiSanto M, Tar M. Longitudinal studies of time-dependent changes in both bladder and erectile function after streptozotocin-induced diabetes in Fischer 344 male rats. BJU Int. 2009;104(9):1292–300. doi:10.1111/j.1464-410X.2009.08573.x, Epub 2009 Apr 15.

    Article  PubMed  Google Scholar 

  83. Christ GJ. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol Clin N Am. 1995;22:727–45.

    CAS  Google Scholar 

  84. Zhang X, Kanika ND, Melman A, DiSanto ME. Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes. Am J Physiol Endocrinol Metab. 2012;302(1):E32–42. doi:10.1152/ajpendo.00231.2011, Epub 2011 Sep 13.

    Article  CAS  PubMed  Google Scholar 

  85. Wei AY, He SH, Zhao JF, liu Y, Liu Y, Hu YW, Zhang T, Wu ZY. Characterization of corpus cavernosum smooth muscle cell phenotype in diabetic rats with erectile dysfunction. Int J Impot Res. 2012;24(5):196–201. doi:10.1038/ijir.2012.16, Epub 2012 May 17.

    Article  CAS  PubMed  Google Scholar 

  86. He S, Zhang T, Liu Y, Liu L, Zhang H, Chen F, Wei A. Myocardin restores erectile function in diabetic rats: phenotypic modulation of corpus cavernosum smooth muscle cells. Andrologia. 2015;47(3):303–9. doi:10.1111/and.12261, Epub 2014 Mar 12.

    Article  CAS  PubMed  Google Scholar 

  87. Lee SW, Wang HZ, Christ GJ. Characterization of ATP-sensitive potassium channels in human corporal smooth muscle cells. Int J Impot Res. 1999;11:179–88.

    Article  CAS  PubMed  Google Scholar 

  88. Lee SW, Wang HZ, Zhao W, Ney P, Brink PR, Christ GJ. Prostaglandin E1 activates the large conductance KCa channel in human corporal smooth muscle. Int J Impot Res. 1999;11:189–99.

    Article  CAS  PubMed  Google Scholar 

  89. Christ GJ, Moreno AP, Melman A, Spray DC. Gap junction-mediated intercellular diffusion of Ca in cultured human corporeal smooth muscle cells. Am J Physiol. 1992;263:C373–83.

    CAS  PubMed  Google Scholar 

  90. Campos de Carvalho AC, Roy C, Moreno AP, et al. Gap junctions formed of connexin 43 are found between smooth muscle cells of human corpus cavernosum. J Urol. 1993;149:1568–75.

    Article  CAS  PubMed  Google Scholar 

  91. Christ GJ, Moreno AP, Parker ME, et al. Intercellular communication through gap junctions: potential role in pharmacomechanical coupling and syncytial tissue contraction in vascular smooth muscle isolated from the human corpus cavernosum. Life Sci. 1991;49:PL195–200.

    Article  CAS  PubMed  Google Scholar 

  92. Zhu JH, Jia RP, Xu LW, Wu JP, Liang K, Su Q. Diabetes mellitus reduces the expression of SK3 in rat cavernous tissues. Zhonghua Nan Ke Xue. 2010;16(3):236–9, Chinese.

    CAS  PubMed  Google Scholar 

  93. Rehman J, Chenven E, Brink P, et al. Diminished neurogenic, but not pharmacological erections in the 2- to 3-month experimentally diabetic F-344 rat. Am J Physiol. 1997;272:H1960–71.

    CAS  PubMed  Google Scholar 

  94. Giraldi A, Wen Y, Geliebter J, Christ GJ. Differential gap junction mRNA expression in human corpus cavernosum: a significant regulatory event in cell-to-cell communication? Urology. 1995;153:508A.

    Google Scholar 

  95. Andersen J, Grine E, Eng CL, et al. Expression of connexin-43 in human myometrium and leiomyoma. Am J Obstet Gynecol. 1993;169:1266–77.

    Article  CAS  PubMed  Google Scholar 

  96. Risek B, Guthrie S, Kumar N, Gilula NB. Modulation of gap junction transcript and protein expression during pregnancy in the rat. J Cell Biol. 1990;110:269–82.

    Article  CAS  PubMed  Google Scholar 

  97. Somlyo AP, Wu X, Walker LA, Somlyo AV. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol. 1999;134:201–34.

    CAS  PubMed  Google Scholar 

  98. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051–4.

    Article  CAS  PubMed  Google Scholar 

  100. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245–8.

    Article  CAS  PubMed  Google Scholar 

  101. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004;101:9121–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Yousif MH, Makki B, El-Hashim AZ, Akhtar S, Benter IF. Chronic treatment with Ang-(1–7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes. J Diabetes Res. 2014;2014:142154.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Villalba N, Contreras C, Hernández M, García-Sacristán A, Prieto D. Impaired Ca2+ handling in penile arteries from prediabetic Zucker rats: involvement of Rho kinase. Am J Physiol Heart Circ Physiol. 2011;300(6):H2044–53.

    Article  CAS  PubMed  Google Scholar 

  104. Li WJ, Park K, Paick JS, Kim SW. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. J Sex Med. 2011;8:400–10.

    Article  CAS  PubMed  Google Scholar 

  105. Sawada N, Itoh H, Yamashita J, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun. 2001;280:798–805.

    Article  CAS  PubMed  Google Scholar 

  106. Surks HK, Mochizuki N, Kasai Y, et al. Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. Science. 1999;286:1583–7.

    Article  CAS  PubMed  Google Scholar 

  107. Hedlund P, Aszodi A, Pfeifer A, et al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci U S A. 2000;97:2349–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Francis SH, Woodford TA, Wolfe L, Corbin JD. Types I alpha and I beta isozymes of cGMP-dependent protein kinase: alternative mRNA splicing may produce different inhibitory domains. Second Messengers Phosphoproteins. 1988;12:301–10.

    CAS  PubMed  Google Scholar 

  109. Wolfe L, Corbin JD, Francis SH. Characterization of a novel isozyme of cGMP-dependent protein kinase from bovine aorta. J Biol Chem. 1989;264:7734–41.

    CAS  PubMed  Google Scholar 

  110. Chang S, Hypolite JA, Velez M, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol. 2004;287:R950–60.

    Article  CAS  PubMed  Google Scholar 

  111. Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJ, Andersson KE, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int. 2007;99(6):1488–94.

    Article  CAS  PubMed  Google Scholar 

  112. Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 2007;21(4):1202–9.

    Article  PubMed  CAS  Google Scholar 

  113. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta. 2006;1758(12):2016–26.

    Article  CAS  PubMed  Google Scholar 

  114. Watterson KR, Ratz PH, Spiegel S. The role of sphingosine-1-phosphate in smooth muscle contraction. Cell Signal. 2005;17(3):289–98.

    Article  CAS  PubMed  Google Scholar 

  115. di Villa Bianca R, Sorrentino R, Sorrentino R, et al. Sphingosine-1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther. 2006;316:703–8.

    Article  PubMed  CAS  Google Scholar 

  116. Vernet D, Cai L, Garban H, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type 1) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology. 1995;136:5709–17.

    Article  CAS  PubMed  Google Scholar 

  117. Davies KP, Tar M, Rougeot C, Melman A. Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int. 2007;99(2):431–5, Epub 2006 Oct 9.

    Article  CAS  PubMed  Google Scholar 

  118. Tong Y, Tar M, Davelman F, Christ G, Melman A, Davies KP. Variable coding sequence protein A1 as a marker for erectile dysfunction. BJU Int. 2006;98:396–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Tong Y, Tar M, Melman A, Davies K. The opiorphin gene (ProL1) and its homologues function in erectile physiology. BJU Int. 2008;102(6):736–40.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Christ G, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol. 2004;287(4):H1544–53.

    Article  CAS  PubMed  Google Scholar 

  121. Kaiser FE, Udhoji V, Viosca SP, et al. Cardiovascular stress tests in patients with vascular impotence. Clin Res. 1989;37:89A.

    Google Scholar 

  122. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1:181–4.

    Article  CAS  PubMed  Google Scholar 

  123. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–4.

    Article  PubMed  Google Scholar 

  124. Jevtich MJ, Edson M, Jarman WD, Herrera HH. Vascular factor in erectile failure among diabetics. Urology. 1982;19:163–8.

    Article  CAS  PubMed  Google Scholar 

  125. Herman A, Adar R, Rubinstein Z. Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease. Diabetes. 1978;27:975–81.

    Article  CAS  PubMed  Google Scholar 

  126. Akoi I, Shimoyama K, Aoki N, et al. Platelet dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulopathy in diabetes. J Am Coll Cardiol. 1996;27:560–6.

    Article  Google Scholar 

  127. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet. 1989;1:461–3.

    Article  CAS  PubMed  Google Scholar 

  128. Carrier S, Brock G, Kour NW, Lue TF. Pathophysiology of erectile dysfunction. Urology. 1993;42:468–81.

    Article  CAS  PubMed  Google Scholar 

  129. Rosen MP, Greenfield AJ, Walker TG, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotent. J Urol. 1991;145:759–63.

    Article  CAS  PubMed  Google Scholar 

  130. Hakim LS, Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin N Am. 1996;25:379–400.

    Article  CAS  Google Scholar 

  131. Krane RJ, Goldstein I, Saenz de Tejada I. Medical progress: impotence. N Engl J Med. 1989;321:1648.

    Article  CAS  PubMed  Google Scholar 

  132. Mottonen M, Nieminen K. Relation of atherosclerotic obstruction of the arterial supply of corpus cavernosum to erectile dysfunction. In: Proceedings of the sixth biennial international symposium on corpus cavernosum revascularization and third biennial world meeting on impotence. Boston: 12, 1988.

    Google Scholar 

  133. Vlachopoulos C. Progress towards identifying biomarkers of vascular aging for total cardiovascular risk prediction. J Hypertens. 2012;30:S19–26.

    Article  CAS  PubMed  Google Scholar 

  134. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology. 1995;45:498–502.

    Article  CAS  PubMed  Google Scholar 

  135. Merckx LA, DeBruyne RM, Goes E, Derde MP, Keuppens F. The value of dynamic color duplex scanning in the diagnosis of venogenic impotence. J Urol. 1992;148:318–20.

    Article  CAS  PubMed  Google Scholar 

  136. Kropman RF, Schipper J, Oostayen JA, Nijeholt ABL, Meinhardt W. The value of increased end diastolic velocity during penile duplex sonography in relation to pathological venous leakage in erectile dysfunction. J Urol. 1992;148:314–7.

    Article  CAS  PubMed  Google Scholar 

  137. Feng Y, Schlösser FJ, Sumpio BE. The Semmes Weinstein monofilament examination is a significant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus. J Vasc Surg. 2011;53(1):220–6.

    Article  PubMed  Google Scholar 

  138. Melman A, Tiefer L, Pedersen R. Evaluation of first 406 patients in urology department based center for male sexual dysfunction. Urology. 1988;32:6–10.

    Article  CAS  PubMed  Google Scholar 

  139. Bleustein CB, Eckholdt H, Arezzo JC, Melman A. Quantitative somatosensory testing of the penis: optimizing the clinical neurological examination. J Urol. 2003;169:2266–9.

    Article  PubMed  Google Scholar 

  140. Nisen HO, Larsen A, Lindstrom BL, Ruutu ML, Virtanen JM, Alfthan OS. Cardiovascular reflexes in the neurological evaluation of impotence. Br J Urol. 1993;71:199–203.

    Article  CAS  PubMed  Google Scholar 

  141. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. J Am Med Assoc. 1999;281:421–6.

    Article  CAS  Google Scholar 

  142. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabetes Med. 1998;15:821–5.

    Article  CAS  Google Scholar 

  143. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl. 2001;22(5):793–7, Erratum in: J Androl 2002 Jan-Feb;23(1):113.

    CAS  PubMed  Google Scholar 

  144. Choi WS, Kwon OS, Cho SY, Paick JS, Kim SW. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats. J Sex Med. 2015;12(3):600–10.

    Article  CAS  PubMed  Google Scholar 

  145. Martínez-Salamanca JI, La Fuente JM, Cardoso J, Fernández A, Cuevas P, Wright HM, Angulo J. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. J Sex Med. 2014;11(5):1182–92.

    Article  PubMed  CAS  Google Scholar 

  146. González-Corrochano R, La Fuente J, Cuevas P, Fernández A, Chen M, Sáenz de Tejada I, Angulo J. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. Br J Pharmacol. 2013;169(2):449–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  147. Fukuhara S, Tsujimura A, Okuda H, Yamamoto K, Takao T, Miyagawa Y, Nonomura N, Okuyama A. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. J Sex Med. 2011;8(4):1061–71.

    Article  CAS  PubMed  Google Scholar 

  148. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med. 2006;3(4):727–35.

    Article  PubMed  Google Scholar 

  149. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med. 2006;3(2):253–64, discussion 264–5, author reply 265–6.

    Article  CAS  PubMed  Google Scholar 

  150. Mostafa T, Rashed LA, Kotb K. Testosterone and chronic sildenafil/tadalafil anti-apoptotic role in aged diabetic rats. Int J Impot Res. 2010;22(4):255–61.

    Article  CAS  PubMed  Google Scholar 

  151. Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs. 1996;51(6):954–65.

    Article  CAS  PubMed  Google Scholar 

  152. Khan MA, Thompson CS, Sullivan ME, Jeremy JY, Mikhailidis DP, Morgan RJ. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostglandins Leukot Essent Fatty Acids. 1999;60:169–74.

    Article  CAS  Google Scholar 

  153. Beaser RS, Van der Hoek C, Jacobson AM, Flood TM, Desautels RE. Experience with penile prosthesis in the treatment of impotence in diabetic men. J Am Med Assoc. 1982;248:943–8.

    Article  CAS  Google Scholar 

  154. Scott FB, Fishman IJ, Light JK. An inflatable penile prosthesis for treatment of diabetic impotence. Ann Intern Med. 1980;92:340–2.

    Article  CAS  PubMed  Google Scholar 

  155. Melman A, Bar-Chama N, Mccullough A, Davies KP, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Sarah Collins, M.D., Urogynecology Fellow at the Albert Einstein College of Medicine, for making valuable contributions in editing the text.

We also want to thank Kelvin Davies, Ph.D., Professor in the Department of Urology at Albert Einstein College of Medicine, for his diagrammatic representation of SM physiology.

Author information

Authors and Affiliations

  1. Department of Urology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

    Arnold Melman

  2. Department of Urology, Kaiser Permanente, Atlanta, Georgia, USA

    Barry Mason

  3. Flushing Hospital Medical Center, Private Practice 13338, 41st road, #2D, Flushing, NY, 11355, USA

    Albert C. Leung

  4. Biomedical Sciences and Surgery, Urology Research, Cooper Medical School of Rowan University, Camden, New Jersey, USA

    Michael E. DiSanto

Authors
  1. Arnold Melman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert C. Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael E. DiSanto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Melman .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Gerald J. Friedman Diabetes Institute, Lenox Hill Hospital, Hofstra Northwell School of Medicine, Northwell Health, New York, New York, USA

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Melman, A., Mason, B., Leung, A.C., DiSanto, M.E. (2017). Male Sexual Dysfunction in Diabetes Mellitus. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Cham. https://doi.org/10.1007/978-3-319-18741-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18741-9_26

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18740-2

  • Online ISBN: 978-3-319-18741-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation